Berkshire Hathaway Inc. vs Novo Nordisk A/S: Strategic Comparison

This in-depth comparison examines Berkshire Hathaway Inc. and Novo Nordisk A/S across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Berkshire Hathaway Inc. on its own, evaluating Novo Nordisk A/S, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Berkshire Hathaway Inc. and Novo Nordisk A/S is widest.

On the headline numbers, Berkshire Hathaway Inc. reports annual revenue of $371.4B against $42.7B for Novo Nordisk A/S, while their respective market capitalizations stand at $1.05T and $550.0B. Berkshire Hathaway Inc. is headquartered in United States and Novo Nordisk A/S operates from Denmark, and those different home markets shape how each company competes.

Berkshire Hathaway Inc.: Few financial facts stop a room quite like this one: a single share of Berkshire Hathaway Class A stock costs more than most Americans earn in a decade. That one data point encapsulates something profound about the institution Berkshire Hathaway has become: an anomaly so extreme it defies the normal categories of corporate analysis. What Buffett built over the following six decades is something that defies easy categorization. It owns GEICO, which insures more than 18 million vehicles. It owns BNSF Railway, which hauls freight across 32,500 miles of track through 28 US states. It owns Berkshire Hathaway Energy, with electric utility operations serving millions of customers. Abel, a Canadian-born executive who built Berkshire Hathaway Energy into a multi-hundred-billion-dollar utility powerhouse, brings operational depth that Buffett himself acknowledged he lacked. The question Wall Street has been asking for fifteen years — what happens after Buffett? — is now being answered in real time, and early evidence suggests Berkshire's culture, capital allocation framework, and institutional identity are more durable than the skeptics predicted. Over more than fifty-five years, that argument has been proven correct with mathematical precision. It does not sell a unified service. It does not operate with traditional corporate hierarchies, shared services infrastructure, or centralized procurement. **The Insurance Float Engine** For Berkshire, under Buffett's direction, float became the raw material of empire. No bank offers this arrangement. No bond market replicates it. GEICO has historically been one of the most cost-efficient auto insurers in the United States. Berkshire Hathaway Reinsurance Group handles massive, complex reinsurance transactions. BHE has faced significant headwinds from wildfire liability issues particularly related to its PacifiCorp subsidiary in Oregon, but remains a core component of Berkshire's infrastructure holdings. Apple remains the single largest position, though trimmed from over 900 million shares to approximately 300 million shares by year-end 2024. American Express, Bank of America, Coca-Cola, Chevron, Occidental Petroleum, Kraft Heinz, and Moody's are among the other major positions. **The Capital Allocation Framework** When the equity portfolio generates dividends, that flows to Omaha. When insurance operations generate underwriting profits, that flows to Omaha. **The Decentralized Operating Model** Berkshire's headquarters in Omaha employs roughly 25 people. Its headquarters in Omaha, Nebraska employs a corporate staff of roughly 25 people who oversee approximately 90 operating subsidiaries employing nearly 396,000 workers across insurance, transportation, energy, manufacturing, retail, and financial services. Its Class A shares trade above $700,000 — a deliberate signal of long-term ownership philosophy. There are no shared services functions, no centralized HR or IT departments, no corporate acquisition integration teams. No single revenue stream dominates, and this diversification has historically provided earnings stability through economic cycles that cyclical or single-industry companies cannot match. The management transition has been deliberately gradual, allowing institutional knowledge, relationships, and cultural continuity to transfer without disruption. Berkshire enters the mid-2020s with record operating earnings, unprecedented cash reserves, and a succession framework designed to endure for another generation. Berkshire Hathaway does not compete in conventional terms. The most direct competitive set for Berkshire's holding company model includes other large diversified conglomerates: 3M, Honeywell, and General Electric historically, though GE's protracted unraveling over two decades stands as a cautionary tale about conglomerate excess rather than a competitive threat to Berkshire. In the private equity world, firms like Blackstone, KKR, and Apollo compete for some of the same acquisition targets, but with structurally different objectives — they manage funds with defined lives and return-of-capital mandates, meaning they must eventually sell their acquisitions. BNSF has faced criticism for service quality and Union Pacific has made gains in certain commodity segments. When Buffett held Coca-Cola stock for over thirty years, he was not subject to the quarterly performance pressure that forces most institutional managers to trade around their convictions. Warren Buffett has repeatedly described his desire to make 'elephant-sized' acquisitions — deals large enough to meaningfully impact Berkshire's earnings. **Wildfire Liability and the BHE Overhang** Berkshire Hathaway Energy's PacifiCorp subsidiary faces billions of dollars in potential liability from Oregon and California wildfires. **The Succession and Cultural Continuity Question** **GEICO's Competitive Position** **Interest Rate and Valuation Sensitivity** Berkshire's enormous equity portfolio — heavily weighted toward financial stocks and consumer brands — creates meaningful exposure to equity market valuations. **The Reputation Premium** The Nebraska Furniture Mart's Rose Blumkin, See's Candies, and dozens of other foundational acquisitions came to Berkshire through this channel. This eliminates enormous overhead costs while preserving entrepreneurial cultures. **Capital Deployment Patience** These stakes provide exposure to diversified commodity and industrial value chains with valuation characteristics reminiscent of early Berkshire acquisitions. Share repurchases, while decelerated in 2024, remain a capital return tool when the stock trades below Buffett and Abel's estimate of intrinsic value. Abel has demonstrated exceptional capital allocation skills through his stewardship of Berkshire Hathaway Energy, transforming it from a regional Iowa utility into a multi-state energy empire. A major market dislocation — a recession, a financial crisis, or a sector-specific collapse — could create the acquisition opportunity that Berkshire has been unable to find. Buffett has noted that Berkshire could deploy $50-100 billion in a suitable acquisition without stress. Insurance, energy infrastructure, and consumer staples remain the most natural areas for elephant-sized deals. Chace was a protégé of Samuel Slater, the British-born industrialist who transplanted the industrial revolution's textile machinery to America and established the foundations of New England's textile industry. By the early 1960s, Berkshire Hathaway was a declining industrial enterprise. By the time the mills required their periodic machinery upgrades, Buffett observed, management would tender for shares at slight premiums to the trading price, then after the tender closed, the stock would fall back below the tender price. Then something went wrong — or rather, something went wrong that ultimately led to everything going right. In 1964, Berkshire's president Seabury Stanton offered to buy out Buffett's shares at $11.50 per share. Buffett agreed verbally. But when the formal tender arrived, Stanton had changed the offer to $11.375 per share — an eighth of a dollar less than the oral agreement. 'It was a terrible mistake,' he would later say, repeatedly and publicly. This was not a dramatic transaction at the time. But it introduced Warren Buffett to the concept that would define Berkshire's model: insurance float. The textile operations were finally closed in 1985, twenty years after Buffett's takeover. The mills had been drained of cash, which had been deployed into far more productive enterprises.

Novo Nordisk A/S: A single molecule generated 215.2 billion Danish Krone in FY2024 sales. Semaglutide — marketed as Ozempic for diabetes and Wegovy for obesity — is the most commercially successful pharmaceutical product of the current decade and possibly the most consequential medicine introduced since statins. Novo Nordisk generated 290.42 billion DKK (approximately $42.7 billion) in total FY2024 revenue, and 74% of that revenue came from one chemical compound first synthesized by the company's researchers. That concentration is simultaneously the source of extraordinary financial performance and the central strategic risk of the entire enterprise. Novo Nordisk's origins in 1923 and 1925 as two separate Danish insulin laboratories trace back to August Krogh, a Danish Nobel laureate who learned of insulin's discovery in Canada in 1922 and obtained a license to manufacture it in Scandinavia. For eight decades, the company operated as a high-quality but relatively constrained insulin manufacturer competing in a global market where Eli Lilly, Sanofi, and others were similarly positioned. The incretin class of drugs — GLP-1 receptor agonists that stimulate insulin secretion while suppressing appetite — changed everything. Semaglutide, the optimized GLP-1 agonist that Novo Nordisk developed over fifteen years of research, proved effective not just for blood sugar control but for substantial, sustained weight loss. The company operates from Bagsværd, Denmark, a suburb of Copenhagen where the research and manufacturing infrastructure that produced semaglutide was built over decades. The 77,900 employees across global manufacturing facilities cannot produce Wegovy and Ozempic fast enough to meet demand — a problem that is simultaneously evidence of unprecedented commercial success and a constraint on revenue growth. Novo Holdings, the controlling shareholder, acquired Catalent in 2024 for $16.5 billion specifically to secure additional manufacturing capacity. CEO Lars Fruergaard Jørgensen has been managing a company that grew from $24.8 billion in FY2022 revenue to $42.7 billion in FY2024 — 72% growth in two years — while simultaneously trying to build the manufacturing infrastructure to support a demand trajectory that no pharmaceutical company in history had previously experienced.

Berkshire Hathaway Inc. and Novo Nordisk A/S pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Berkshire Hathaway Inc. and Novo Nordisk A/S.

Berkshire Hathaway Inc. business model: All of these elements feed into the central function: capital allocation. Honestly, Berkshire generates revenue from an extraordinarily diverse set of sources: insurance premiums, freight revenues, electricity sales, manufactured goods, wholesale distribution, restaurant royalties, aircraft chartering, and dozens of other business lines. Berkshire never sells, and that permanence is itself a competitive differentiator that private equity cannot match. The real competitive battle is for shipper relationships, pricing discipline, and service reliability. But Berkshire's competitive position here is unique: it does not manage outside capital, has no redemption pressures, pays no management fees, and can hold positions for decades without client reporting pressure. Berkshire Hathaway Energy's contribution to earnings was complicated by wildfire-related reserve charges. GEICO experienced significant underwriting losses in 2022 and faced market share erosion as Progressive Corporation surged ahead using telematics-based pricing that more precisely matched premiums to actual driver risk.

Novo Nordisk A/S business model: For the first 80 years of its existence, the organization operated primarily as a low-margin, high-volume manufacturer of animal-derived and later recombinant human insulins, competing in a crowded market where pricing was heavily regulated by European national health systems and US government procurement contracts. The pricing power inherent in the innovative pharma model allows Novo Nordisk to charge premium list prices in the US market, which accounts for approximately 65% of total global sales. However, this pricing power is heavily distorted by the US pharmacy benefit manager (PBM) system. Novo Nordisk's Insulin glargine (Levemir) and Insulin aspart (NovoLog) are locked in a price war with Sanofi's Lantus and Eli Lilly's Humalog, a battle that has been exacerbated by the introduction of interchangeable biosimilars and the aggressive pricing tactics of the big three PBMs in the US. This strategy of identifying unmet medical needs in complex, chronic diseases and developing targeted therapies to address them is a core component of Novo Nordisk's competitive strategy, allowing the company to command premium pricing and achieve high margins despite the intense competitive pressure in the broader metabolic disease market. While legacy insulin sales declined by 4% due to biosimilar competition and VBP pricing pressure in China, the combined sales of Ozempic (146.9 billion DKK), Wegovy (68.2 billion DKK), and Rybelsus (2.8 billion DKK) demonstrated that the next generation of incretin therapies is achieving commercial scale faster than anticipated. The US market remains the most profitable region, contributing approximately 65% of total revenue but an even higher percentage of operating profit due to the significantly higher pricing power for innovative biologics in the United States compared to Europe and Asia. Concurrently, the company is navigating intense structural pricing pressure in the US, the world's most profitable pharmaceutical market. While the FDA has recently cracked down on these practices, the existence of a parallel, low-cost supply chain has permanently altered patient expectations regarding the pricing of GLP-1 therapies, making it increasingly difficult for Novo Nordisk to maintain its premium list prices without facing intense public and political backlash. The company's deep integration with academic medical centers through its clinical trial network creates a feedback loop of real-world data that accelerates regulatory approvals and label expansions, further entrenching its dominance in the therapeutic area. The company must also navigate the complex and evolving pricing and reimbursement landscape, particularly in the US where the implementation of the Inflation Reduction Act is expected to put significant downward pressure on drug prices.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Berkshire Hathaway Inc. stack up against those of Novo Nordisk A/S.

Berkshire Hathaway Inc. competitive advantage: The conglomerate's financial scale is staggering. It is the structural advantage that made everything else possible. This capital discipline — the willingness to hold enormous cash reserves and wait rather than deploy capital at mediocre returns — is, paradoxically, one of Berkshire's most powerful competitive advantages. The competitive dynamics here are relatively stable — railroads are natural monopolies or duopolies within geographic territories, and the barriers to entry (capital requirements, land, regulatory approvals) are essentially insurmountable. The deepest competitive moat, however, is cultural and reputational, and it manifests most powerfully in acquisition dynamics. This reputational moat took decades to build and would take decades to erode, making it Berkshire's most durable long-term competitive advantage. As Berkshire's scale has grown, its addressable deal universe has shrunk. Additionally, Berkshire's investment in fixed-income instruments is influenced by interest rate cycles, and any sharp normalization in rates in either direction creates portfolio management complexity at the scale Berkshire operates. Berkshire Hathaway's competitive advantages are structural, cultural, and reputational — and they compound over time in ways that create barriers to imitation that no single rival can overcome. **The Float Advantage** This structural advantage has been described by financial academics as the single most important factor in Berkshire's long-term outperformance relative to the S&P 500. **Decentralized Management Scale** No traditional conglomerate has successfully replicated this model at scale. When markets dislocate, Berkshire can act at extraordinary scale and speed. Berkshire's diverse business portfolio creates unusual informational advantages. On the acquisition front, Berkshire is explicitly targeting businesses with durable competitive advantages, predictable earnings, honest management, and prices that make economic sense for a permanent, non-selling owner. Buffett's stated preference remains for 'simple businesses we understand' with returns on equity above 15%, low debt, and sustainable moats. But the structural disadvantage was insurmountable.

Novo Nordisk A/S competitive advantage: The execution of this strategy requires flawless commercial execution and unprecedented manufacturing scale, capabilities that were severely tested in 2023 when the FDA issued warnings to compounding pharmacies that were illegally producing unapproved versions of semaglutide to bypass the official supply shortages. The successful completion of these trials has established semaglutide as a foundational therapy for cardiorenal protection, a competitive advantage that is extremely difficult for new entrants to replicate without conducting their own multi-year, multi-billion dollar outcomes trials. This specific molecular architecture is protected by a dense thicket of composition-of-matter, formulation, and method-of-use patents that do not expire until the mid-2030s, creating a legal barrier to entry that is virtually impossible to close quickly. This clinical data package, encompassing over 100,000 patient-years of exposure across the STEP, SUSTAIN, PIONEER, and SELECT trial programs, represents a competitive advantage that is rooted in deep scientific expertise, massive capital barriers, and regulatory exclusivity. The manufacturing moat is equally formidable. Novo Nordisk operates the largest peptide fermentation facilities in the world, located in Kalundborg, Denmark, which are specifically designed to handle the complex biological processes required to produce semaglutide at commercial scale. The sheer cost and regulatory complexity of building and operating these facilities deter all but the most well-capitalized competitors from attempting to enter the GLP-1 space, giving Novo Nordisk a significant cost and scale advantage that will be difficult to replicate. This regulatory expertise, combined with its manufacturing scale and clinical data dominance, creates a comprehensive competitive advantage that positions Novo Nordisk as the undisputed leader in the rapidly evolving field of incretin therapies. The commercial infrastructure required to support this advantage is equally specialized. If these trials are successful, Novo Nordisk could potentially launch semaglutide for MASH by 2027, establishing another first-mover advantage in a completely new therapeutic area and creating a multi-billion dollar revenue stream that would significantly diversify the company's portfolio. Novo Nordisk has established a dedicated AI and data science hub in Copenhagen, which is focused on developing machine learning algorithms to analyze large-scale biological datasets, identify novel peptide targets, and optimize the design of clinical trials.

Future prospects matter as much as current results. The growth strategies below explain how Berkshire Hathaway Inc. and Novo Nordisk A/S each plan to expand from here.

Berkshire Hathaway Inc. growth strategy: It was purchased by a young Omaha-based partnership manager named Warren Buffett not as a foundation for empire-building but, by his own repeated admission, as a mistake — a 'cigar butt' investment he grabbed because the price was cheap, even though the underlying business was fundamentally impaired. Berkshire Hathaway is simultaneously an insurance company, a railroad operator, a utility provider, a manufacturer, a retailer, a financial services firm, and one of the world's largest equity investment portfolios. The company's equity investment portfolio, though reduced from peak Apple concentration, still carries tens of billions in positions across financial services, consumer staples, and energy. This radical decentralization is not a management flaw but a deliberate philosophy: Berkshire acquires exceptional businesses run by exceptional managers and then, in Buffett's words, gets out of their way. The company also manages one of the largest equity investment portfolios in the world, with significant positions in Apple, American Express, Bank of America, and Coca-Cola. Instead, Berkshire Hathaway is, at its most fundamental level, a capital allocation machine — an entity whose core competency is identifying excellent businesses, acquiring them at reasonable prices, retaining exceptional managers, and then redeploying the cash those businesses generate into new investments over extremely long time horizons. The time gap between premium collection and claim payment generates a pool of investable cash called float. For most insurance companies, this float is a liability — an obligation that must be managed carefully and invested conservatively. This is money that does not belong to Berkshire in the traditional sense — it will eventually be paid out in claims — but in the meantime, Berkshire gets to invest it. **The Equity Investment Portfolio** When Berkshire's operating businesses generate more cash than they need for maintenance and organic growth, that cash flows to Omaha. And then Berkshire decides where to deploy it next — acquisitions, equity investments, stock buybacks, or Treasury bills to wait for the next opportunity. This radical decentralization eliminates corporate overhead, preserves the entrepreneurial cultures that made acquired companies excellent in the first place, and allows Berkshire to own vastly more businesses than any traditional conglomerate could manage. The model works because Berkshire acquires businesses with proven management already in place, and then trusts those managers rather than imposing corporate bureaucracy on them. The company's investment portfolio holds hundreds of billions in publicly traded equities. This structure was designed by Warren Buffett to preserve the entrepreneurial cultures that made acquired businesses excellent while eliminating the bureaucratic overhead that typically expands with corporate scale. The irony is, the competitive response under Todd Combs, who took operational control of GEICO, has involved significant technology investment, a reduction in advertising spend in favor of profitability, and aggressive rate increases to restore underwriting margins. But both railroads face the longer-term structural question of whether coal traffic decline will be offset by intermodal and agricultural growth. BHE has historically differentiated through aggressive investment in renewable energy — it was among the first US utilities to commit to zero-carbon electricity generation across its service territories. However, the wildfire liability crisis related to PacifiCorp has created financial uncertainty and diverted management attention from growth investments, potentially allowing better-capitalized competitors to advance renewable development programs more aggressively. This operating earnings figure reflects the combined pre-tax earnings of all Berkshire's subsidiaries plus investment income, minus corporate expenses and taxes. Berkshire's book value per share grew to approximately $459,000 per Class A equivalent share, and the stock's price-to-book ratio expanded as investor confidence in the post-Buffett transition grew. Berkshire's brand is inseparable from Warren Buffett in the minds of most investors. When that float is generated at zero cost or below (underwriting profit), Berkshire effectively receives free financing to invest across its portfolio. Berkshire's reputation as a permanent, hands-off acquirer commands a premium in deal negotiations. Business owners who have spent decades building their companies — and care deeply about what happens to their employees, their culture, and their customers after they sell — often choose Berkshire over private equity buyers who offer higher prices but come with integration plans, cost-cutting mandates, and eventual re-sale. This was demonstrated during the 2008 financial crisis (investments in Goldman Sachs and GE on highly favorable terms) and repeatedly in subsequent market dislocations. Management insights from BNSF's freight volumes, McLane's distribution data, and GEICO's customer demographics collectively provide Buffett and Abel with a real-time economic dashboard that few investors or operators can match. Berkshire Hathaway's growth strategy, as articulated in Buffett's annual letters and operationalized under Greg Abel's day-to-day leadership, centers on disciplined capital allocation across four channels: wholly-owned business acquisitions, equity investment portfolio additions, organic investment within existing subsidiaries, and opportunistic share repurchases. Within existing businesses, Berkshire is pursuing significant capital investment programs. BNSF plans to invest billions annually in track infrastructure, technology, and operational efficiency improvements. Berkshire Hathaway Energy is executing a multi-decade transition toward renewable generation, with wind, solar, and transmission infrastructure investments running into the tens of billions. These organic investment channels allow Berkshire to deploy substantial capital into businesses it already understands deeply. Japan has emerged as an interesting international growth vector. As intrinsic value grows with operating earnings, the buyback calculation will periodically favor repurchases over cash accumulation. Berkshire Hathaway Energy's clean energy transition represents one of the most significant growth opportunities: the company has committed to massive renewable energy investment and could accelerate that investment as wildfire liability clarity emerges. Enter Warren Edward Buffett, a 32-year-old investor from Omaha who had learned the craft of value investing under Benjamin Graham at Columbia Business School and subsequently managed a highly successful investment partnership in Omaha. Buffett's partnership had already accumulated modest profits in various industries when, in 1962, he noticed that Berkshire Hathaway's stock was trading at approximately $7.50 per share while the company's working capital alone was worth considerably more. It was a pattern Buffett recognized from Graham's 'net-net' investment framework — buying a dollar of value for significantly less than a dollar of price. By 1965, Buffett's partnership controlled Berkshire Hathaway and Buffett replaced Stanton as president. The irony was immediately apparent: Buffett had acquired control of a business he knew was fundamentally impaired. The textile mills continued to require capital investment that never earned adequate returns. Buffett tried for nearly two decades to make the textile operation viable, investing in new machinery, exploring different product lines, and working with management to reduce costs. National Indemnity's float — the gap between premiums collected and claims paid — gave Buffett investable capital at a cost that approached zero when underwriting was profitable. He recognized immediately that this was the ideal financing structure for his investment approach: patient, permanent capital with no redemption risk and potentially negative carrying costs. He would spend the next five decades building the world's largest collection of insurance operations around this insight. The Berkshire Hathaway name survived as the holding company's brand — a perpetual reminder, Buffett has said, of the 'penalty' he paid for an emotional investment decision in 1964.

Novo Nordisk A/S growth strategy: The introduction of Victoza (liraglutide) in 2009 marked the first shift toward incretin therapies, but it was the 2017 launch of Ozempic and the 2021 launch of Wegovy that triggered a paradigm shift in global medicine, transforming obesity from a lifestyle condition treated with behavioral counseling into a chronic neurological disease requiring lifelong pharmacological intervention. The remaining 26% of revenue is generated by legacy insulin analogs (Insulin glargine, Insulin aspart), growth hormone therapies, and hemophilia treatments, a portfolio that is growing at a low single-digit rate and serves primarily as a stable cash-flow baseline. To mitigate the risks associated with this extreme concentration, the business model incorporates aggressive inorganic growth and massive organic capital expenditure. The company uses its substantial free cash flow to acquire clinical-stage biotechnology companies and secure manufacturing capacity. This vertical integration strategy is designed to control the entire value chain, from the bacterial fermentation of the semaglutide peptide in Kalundborg, Denmark, to the final assembly of the FlexTouch injection pens in Hillerød, Denmark, and Clayton, North Carolina. This dynamic forces the company to maintain exceptionally high list prices to preserve its net revenue margins, a strategy that attracts intense political and regulatory scrutiny in the US and Europe. The ultimate goal of the business model is to achieve a sustainable compound annual growth rate (CAGR) of 15-20% at constant currency through 2030, a target that requires the successful launch of next-generation assets like CagriSema and oral amycretin, and the continuous expansion of manufacturing capacity to meet the estimated 1 billion obese patients globally who are candidates for pharmacological intervention. This logistical constraint creates a massive barrier to entry for competitors, as it requires the establishment of a decentralized network of specialized fill-finish facilities and cold-chain distribution partners, a capital-intensive infrastructure that Novo Nordisk has spent the last decade building through strategic acquisitions and organic investment. For Ozempic, the company has continuously expanded the label to include new indications such as cardiovascular risk reduction (based on the SELECT trial data) and chronic kidney disease, while also launching higher-dose formulations to improve glycemic control. The company's research centers in Bagsværd, Måløv, Oxford, and Cambridge focus on advanced areas such as oral peptide delivery, multi-receptor agonism, and gene editing. Novo Nordisk's response has been to pivot its diabetes portfolio toward combination therapies, such as the fixed-ratio combination of Insulin degludec and liraglutide (Xultophy), and to position its GLP-1 assets as the primary growth engine for the future. Novo Nordisk's competitive strategy in this space relies on continuous lifecycle management, launching new formulations and delivery methods to extend patent life and maintain premium pricing. To counter this, Novo Nordisk has adopted a 'buy and partner' strategy, using its massive balance sheet to acquire clinical-stage biotechs and secure exclusive rights to early-stage assets like Zealand Pharma's amycretin, effectively outsourcing the early-stage discovery risk to the private markets and then using its global commercial infrastructure to maximize the value of the assets. Novo Nordisk has responded by aggressively expanding its cardiovascular outcomes trial program, conducting the FLOW trial to evaluate the impact of semaglutide on chronic kidney disease, and the SELECT trial to evaluate its impact on major adverse cardiovascular events in non-diabetic obese patients. Selling, general, and administrative expenses were tightly controlled, growing at a slower rate than revenue, which contributed to the margin expansion. This capital return strategy is designed to support the stock price during the transition period between legacy insulin patents and new GLP-1 launches, signaling management's confidence in the long-term cash generation capabilities of the incretin-focused model. The FY2024 financial performance validates the strategic decision to pivot aggressively toward obesity therapeutics, as the removal of the low-margin legacy insulin focus has significantly improved the company's overall profitability metrics and return on invested capital. This substantial R&D investment is critical for maintaining the company's competitive position and driving future growth, and it is allocated across a diverse portfolio of early-stage discovery programs, Phase I and II clinical trials, and large-scale Phase III registrational studies like the SELECT and FLOW trials. Selling, general, and administrative (SG&A) expenses were 73.5 billion DKK, or 25.3% of net sales, reflecting the significant commercial investment required to launch and support the company's growing portfolio of GLP-1 therapies and navigate the complex PBM rebate landscape. The balance sheet at the end of FY2024 showed total assets of 412.5 billion DKK, total liabilities of 245.3 billion DKK, and total equity of 167.2 billion DKK, resulting in a debt-to-equity ratio of 0.65, which is well within the company's target range and provides a strong foundation for future growth and capital allocation initiatives. The implementation of the Inflation Reduction Act has enabled Medicare to negotiate drug prices, and while GLP-1s are currently excluded from the initial negotiation rounds due to their recent approval dates, the political momentum to include obesity therapies in future negotiations is growing rapidly. The commercial coverage of Wegovy for obesity is highly fragmented, with only a small percentage of commercial insurance plans and almost no Medicare plans covering the drug for weight loss alone, forcing Novo Nordisk to rely heavily on out-of-pocket payments and manufacturer copay cards, a strategy that is financially unsustainable in the long term. Finally, the company must manage the operational complexity of a massively expanded manufacturing footprint. Additionally, the company faces significant headwinds in the Chinese market, which has historically been a key driver of volume growth for its insulin portfolio. Novo Nordisk has responded by restructuring its commercial organization in China, shifting its focus toward a smaller portfolio of high-value innovative medicines like Ozempic, but the long-term impact of these regulatory pricing pressures on the company's growth trajectory in Asia remains a significant area of uncertainty for investors. The company's extensive experience in navigating the complex regulatory landscape for biologics, which involves coordination between multiple government agencies including the FDA, the EMA, and the WHO, provides it with a deep institutional knowledge base that accelerates the development and commercialization of new peptide assets. Novo Nordisk has invested billions of dollars in developing the FlexTouch and FlexTouch Plus injection devices, which are engineered to minimize injection site pain and ensure accurate dose delivery, a critical factor for patient compliance in chronic obesity treatment. Novo Nordisk A/S's growth strategy is built on three specific, named initiatives with clear financial targets: the acceleration of next-generation incretin therapy launches, the aggressive expansion of global manufacturing capacity through strategic acquisitions and organic investment, and the lifecycle management of key diabetes franchises. The company has committed to launching at least five new molecular entities or major label expansions between 2024 and 2030, a pipeline that includes potential blockbusters in obesity, diabetes, cardiovascular disease, and rare diseases. The incretin initiative is the cornerstone of this strategy, with the company investing heavily in clinical trials and manufacturing capacity to launch CagriSema, oral amycretin, and next-generation multi-receptor agonists. The manufacturing growth strategy focuses on eliminating the physical supply constraints that have limited Wegovy sales by executing a 28.6 billion DKK capital expenditure program to expand API and FDF capacity. The diabetes lifecycle management strategy aims to extend the commercial life of Insulin degludec and Insulin icodec by launching new combination therapies, such as fixed-ratio combinations with GLP-1 receptor agonists, and expanding into new indications like cardiovascular risk reduction. By continuously expanding the clinical utility of these assets, Novo Nordisk can defend against biosimilar competition and maintain premium pricing in key markets. To fund these initiatives, the company maintains a disciplined capital allocation framework that prioritizes R&D investment and targeted manufacturing acquisitions over large-scale, transformational mergers. The acquisition of Catalent and the partnership with Zealand Pharma exemplify this approach, providing the company with de-risked, late-stage assets and critical manufacturing capacity that can be integrated into the existing commercial infrastructure to drive immediate revenue growth. The execution of this growth strategy requires a highly skilled and motivated workforce, and Novo Nordisk has invested heavily in talent acquisition and development to ensure that it has the necessary scientific and commercial expertise to succeed. Novo Nordisk has also implemented a comprehensive training and development program for its employees, focusing on building the skills and capabilities required to succeed in the rapidly evolving pharmaceutical industry. The company's culture of innovation and collaboration is a key enabler of its growth strategy, fostering an environment where employees are encouraged to think creatively, take calculated risks, and work together to solve complex scientific and commercial challenges. The growth strategy also includes a strong focus on sustainability and corporate social responsibility, recognizing that the long-term success of the company is inextricably linked to the health and well-being of the communities in which it operates. Novo Nordisk has committed to achieving net zero greenhouse gas emissions across its value chain by 2030, and has implemented a comprehensive environmental, social, and governance (ESG) program that focuses on reducing its environmental footprint, promoting diversity and inclusion, and ensuring access to healthcare for underserved populations. The company's ESG initiatives are integrated into its overall business strategy, and its performance against these goals is regularly monitored and reported to stakeholders. The successful execution of Novo Nordisk's growth strategy will require the company to navigate a complex and dynamic external environment, characterized by rapid technological change, intense competition, and evolving regulatory and pricing pressures. However, the company's strong scientific heritage, strong pipeline, and disciplined capital allocation strategy provide a solid foundation for future growth, and its commitment to innovation and patient-centricity positions it well to deliver on its strategic objectives and create significant value for all stakeholders. The company projects a 15-20% constant currency sales CAGR from 2024 to 2030, a growth rate that relies heavily on the successful commercial launch of next-generation pipeline assets currently in Phase III trials. In the diabetes space, the launch of Insulin icodec (Awiqli), a once-weekly basal insulin, is expected to drive significant revenue growth and displace legacy daily insulin analogs, a therapeutic area where Novo Nordisk now holds a near-monopoly position in the weekly dosing category. Novo Nordisk has partnered with leading AI companies to identify novel peptide sequences and predict patient responses to therapy, a strategy that could significantly reduce the time and cost required to bring new drugs to market. In addition to GLP-1s, Novo Nordisk is heavily invested in the development of gene therapies and RNA-based therapeutics for rare bleeding disorders and rare endocrine diseases. The company's pipeline includes several gene therapy programs for hemophilia A and B, as well as a strong portfolio of siRNA therapeutics developed through its internal research and external partnerships. Novo Nordisk has invested heavily in its gene therapy manufacturing facilities in Denmark and the US, and has established a dedicated commercial team to support the launch of these complex therapies. The company is also exploring the use of digital biomarkers and wearable devices to collect real-time patient data during clinical trials, which could provide more sensitive and objective measures of drug efficacy and accelerate the regulatory approval process. The successful implementation of these digital health initiatives has the potential to significantly improve the productivity of the company's R&D organization and reduce the attrition rate of clinical candidates, ultimately leading to the faster and more efficient development of new medicines. The company faces intense competition in all of its key therapeutic areas, and the failure of any of its late-stage pipeline assets could have a material adverse impact on its financial performance and growth trajectory. Despite these challenges, Novo Nordisk's strong portfolio of innovative medicines, strong pipeline, and disciplined capital allocation strategy position it well to deliver sustained long-term growth and create significant value for its shareholders. Nordisk focused on purification and prolonged-action insulins, while Novo pioneered the use of recombinant DNA technology to produce human insulin. The early years of Novo Nordisk were marked by constant restructuring and a series of high-profile acquisitions designed to fill pipeline gaps, including the purchase of Genentech's insulin production rights and the expansion into hemophilia and growth hormone therapies.

A closer look at the financial trajectory of Berkshire Hathaway Inc. and Novo Nordisk A/S rounds out the comparison.

Berkshire Hathaway Inc.: In fiscal year FY2025, Berkshire reported total revenues of approximately $371.4B, making it consistently one of the top five companies in the United States by revenue. Its cash and Treasury bill holdings reached a record $334 billion by the end of 2024 — a war chest so large it amounts to more than the annual GDP of many sovereign nations. In FY2025, Berkshire reported revenues of approximately $371.4B and net earnings of roughly $88.4 billion, with an extraordinary cash reserve of $334 billion. With approximately 396,000 employees across its subsidiaries and a market capitalization exceeding $1 trillion as of 2025, Berkshire Hathaway represents the ultimate expression of long-term, value-based investing philosophy translated into institutional form. As of year-end 2024, Berkshire's insurance float stood at approximately $174 billion. This is the extraordinary achievement: Berkshire is effectively paid to hold $174 billion in investable capital. The problem is, GEICO, acquired fully in 1996 for approximately $2.3 billion, serves as the retail insurance flagship — insuring automobiles for more than 18 million policyholders through direct marketing that eliminates agent commissions. General Re, acquired in 1998 for approximately $22 billion in stock, provides global property and casualty and life/health reinsurance. Together, these entities generate premium revenues exceeding $80 billion annually while feeding the float engine. BNSF Railway, acquired in 2010 for $44 billion (including assumed debt), is one of North America's two largest freight railroads. BNSF generates revenues consistently exceeding $23 billion annually. Berkshire's manufacturing segment includes Precision Castparts (aerospace components, acquired for $37.2 billion in 2016 — Berkshire's largest acquisition), Iscar (metal cutting tools), Marmon (industrial components), CTB (agricultural equipment), Forest River (recreational vehicles), and dozens of other industrial manufacturers. The service and retail segment includes NetJets (fractional aircraft ownership), FlightSafety (pilot training), Berkshire Hathaway Automotive (auto dealerships), and McLane Company (wholesale distribution to convenience stores and restaurants), which alone generates revenues exceeding $60 billion annually through its distribution operations. Consumer brands within the portfolio include GEICO (already noted), See's Candies (acquired 1972 for $25 million, now generating pre-tax earnings of over $150 million annually on revenues around $550 million), Dairy Queen (acquired 1997), Fruit of the Loom, Duracell (batteries), Brooks Running, and Helzberg Diamonds. Berkshire maintains a publicly disclosed equity investment portfolio that as of early 2025 carries a market value in excess of $300 billion, though the actual composition has shifted significantly as Berkshire reduced its Apple position throughout 2024. In FY2025 alone, Berkshire repurchased approximately $2.9 billion of its own stock. It allowed cash to accumulate to a record $334 billion when attractive opportunities weren't available at acceptable prices. Berkshire Hathaway Inc. is a Diversified Holding Company / Financial Services company with $371.4B in FY2025 revenue and 396K employees worldwide. Its insurance float provides $174 billion in essentially free investable capital. The competitive threat that deserves the most serious attention over the next decade is not from a specific company but from structural market change: the shrinking universe of businesses large enough to matter to a $1 trillion company. Total revenues for FY2025 came in at approximately $371.4B, continuing the company's position as one of the highest-revenue corporations in the United States — a rank driven substantially by McLane Company's pass-through distribution revenues and BNSF's freight operations. Net earnings attributable to Berkshire shareholders reached approximately $88.4 billion in FY2025, though Buffett consistently urges investors to focus on operating earnings rather than GAAP net income, which is heavily distorted by unrealized investment gains and losses that must be marked to market under current accounting rules. Operating earnings — the figure Buffett considers the most meaningful measure of Berkshire's economic performance — came in at approximately $47.4 billion for FY2025, a record high. BNSF contributed revenues of approximately $23.4 billion, though earnings were pressured by volume declines in certain commodity segments and ongoing infrastructure investment. The most attention-grabbing figure in Berkshire's 2024 financials, however, was the cash and short-term Treasury position, which reached $334 billion by year-end — a staggering accumulation that reflected both strong operating cash generation and Buffett's inability to find large acquisitions at prices he considered reasonable. Berkshire repurchased approximately $2.9 billion of its own stock during 2024, a notable deceleration from prior years, consistent with the stock's premium valuation limiting buyback economics. With a market capitalization exceeding $1 trillion and cash reserves of $334 billion as of year-end 2024, a $5 billion acquisition barely registers. Even a $20 billion deal — enormous by any standard — represents less than 2% of Berkshire's market cap. The 2020 Labor Day fires and subsequent litigation have resulted in jury verdicts and settlements that could expose Berkshire to losses in the range of $10 billion to $15 billion according to some estimates, though outcomes remain uncertain. The insurance float of $174 billion as of year-end 2024 represents a cost of capital advantage unavailable to any non-insurance competitor. Berkshire's willingness to hold $334 billion in cash and Treasury bills while waiting for exceptional opportunities — rather than deploying capital at mediocre returns — creates a permanent option value. Berkshire has accumulated significant positions in five major Japanese trading companies — Itochu, Marubeni, Mitsubishi, Mitsui, and Sumitomo — with a combined investment value exceeding $23 billion as of early 2025. Berkshire has repurchased over $75 billion of its own stock since 2018, generating significant per-share value for remaining shareholders. Berkshire Hathaway's future outlook is shaped by three converging forces: the management transition to Greg Abel, the deployment question surrounding its $334 billion cash reserve, and the structural evolution of its largest businesses in a changing economic environment. The $334 billion cash reserve represents both opportunity and pressure. In 1967, for $8.6 million, Berkshire acquired National Indemnity Company and National Fire & Marine Insurance Company, two Omaha-based insurers.

Novo Nordisk A/S: Revenue grew from $24.8 billion in FY2022 to $33.4 billion in FY2023 to $42.7 billion in FY2024 — a two-year compound growth rate of approximately 31% that is, for a company of this size, essentially without precedent in pharmaceutical history. Operating profit reached 125.3 billion DKK in FY2024, with an operating margin of 43.1%. Free cash flow of 91.2 billion DKK was deployed partially into the record 28.6 billion DKK capital expenditure program to expand manufacturing capacity. The semaglutide franchise breakdown illustrates the market's composition: Ozempic (diabetes indication) generated 146.9 billion DKK, Wegovy (obesity indication) generated 68.2 billion DKK. The obesity market is structurally larger than the diabetes market in terms of addressable population, and Wegovy's growth rate in FY2024 significantly exceeded Ozempic's — suggesting that the revenue mix will continue shifting toward obesity over the medium term as manufacturing constraints ease and insurance coverage expands. The capital expenditure program of 28.6 billion DKK in FY2024 — the largest in European pharmaceutical history — reflects the magnitude of the capacity constraint. Novo Nordisk's active pharmaceutical ingredient production and sterile fill-finish capabilities cannot scale quickly; the regulatory requirements for pharmaceutical manufacturing mean that new capacity requires years of construction and validation before it can produce commercial product. Novo Holdings' acquisition of Catalent was intended to accelerate that timeline by acquiring existing validated facilities rather than building from scratch. The $550 billion market capitalization at fiscal year-end made Novo Nordisk the most valuable company in Europe by a significant margin, representing approximately 12.9x FY2024 revenue. That multiple prices in continued semaglutide dominance, successful next-generation product launches, and the expansion of GLP-1 indications beyond diabetes and obesity into cardiovascular disease, chronic kidney disease, and potentially other metabolic conditions.